PMID: 7543292Jul 1, 1995Paper

In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene

Annals of Hematology
A P StegmannJ E Landegent

Abstract

The deoxycytidine kinase (dck) gene encodes the enzyme responsible for the metabolic activation of the antileukemic drugs cytosine arabinoside (AraC) and 5-aza-2'-deoxycytidine (decitabine, DAC). The dck locus was analyzed at the chromosomal and the molecular level in a model of rat leukemic cell lines, in which AraC and DAC resistance was induced, that was marked by dck deficiency. At the chromosomal level, karyotype analysis of metaphase spreads revealed the presence of an aberrant 2q + chromosome in the AraC-resistant cell line and a (Xq:11q) translocation in its subclone RA/7. The DAC-resistant lines were identical to the parental RCL/O. Fluorescence in situ hybridization on normal rat fibroblast metaphase spreads localized the rat dck gene to chromosome 14q21-q22, a region that was not involved in any of the observed karyotypic aberrations. Analysis at the molecular level revealed an identical rearrangement of the dck gene in the AraC-resistant cell line RCL/A and its subclone RA/7 that resulted in the absence of dck expression, as assessed by RT-PCR. No genomic rearrangements were observed in a DAC-resistant cell line RCL/D or in its subclone RD/1. However, detection of a single-stranded conformation polymorphism (SSCP) a...Continue Reading

References

Jan 1, 1979·Cytogenetics and Cell Genetics·A HagemeijerD Bootsma
Jan 1, 1990·International Journal of Cell Cloning·A C MartensA Hagenbeek
Nov 1, 1989·Somatic Cell and Molecular Genetics·A M ChanC S Cooper
Mar 25, 1983·Nucleic Acids Research·U NudelD Yaffe
Sep 15, 1982·Biochemical Pharmacology·P P MajorD W Kufe
Dec 15, 1994·Gene·A P StegmannJ E Landegent
Jan 1, 1994·Cytogenetics and Cell Genetics·J M de StoppelaarB Hoebee
Apr 15, 1993·European Journal of Biochemistry·P N VanH D Söling

❮ Previous
Next ❯

Citations

Apr 6, 2011·Breast Cancer Research and Treatment·Ernst-Jan GeutjesRené Bernards
Jul 27, 2002·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Vincent GrégoirePierre Scalliet
Jun 17, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Neslihan Aygun KocabasMatthew M Ames
Apr 28, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Valeria SebastianiChristine A Iacobuzio-Donahue
Aug 23, 2011·PloS One·Taichun QinJean-Pierre J Issa
May 1, 2008·Expert Opinion on Drug Discovery·Moshe Szyf
Aug 28, 2012·Advanced Drug Delivery Reviews·Shujun Liu
May 18, 2001·Best Practice & Research. Clinical Haematology·P Sonneveld, A F List
Nov 14, 2006·Clinica Chimica Acta; International Journal of Clinical Chemistry·Syu-ichi KannoMasaaki Ishikawa
Dec 3, 2014·International Journal of Pharmaceutics·Andrei MaksimenkoPatrick Couvreur
Mar 19, 2019·Frontiers in Genetics·Samantha L GoldmanChristopher E Mason
Jul 2, 2010·Pharmaceuticals·Paul M HowellHung T Khong
Oct 31, 2002·European Journal of Haematology·Marjan J T VeugerRenée M Y Barge

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.